CB1 cannabinoid receptor participates in the vascular hyporeactivity resulting from hemorrhagic shock in rats

Chinese Medical Journal

Volumn 122, Issue 8, 2009, Pages 950-954

  Hou, Li Chao ^a   Li, Nan ^a   Zheng, Li Na ^a   Lu, Yan ^a   Xie, Ke Liang ^a   Wang, Yue Min ^b   Ji, Gen Lin ^a   Xiong, Li Ze ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CB1 cannabinoid receptor; Hemorrhagic shock; Vascular hyporeactivity

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; MESSENGER RNA; NORADRENALIN; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HEMORRHAGIC SHOCK; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERIOR MESENTERIC ARTERY; SURVIVAL RATE; VASCULAR DISEASE; VASCULAR HYPOREACTIVITY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; GENE EXPRESSION REGULATION; HYPOTENSION; MALE; PIPERIDINES; PYRAZOLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SHOCK, HEMORRHAGIC; SURVIVAL RATE;

EID: 68249139765     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.08.014     Document Type: Article

References (28)

1. Zweifach BW, Thomas L. The relationship between the vascular manifestations of shock produced by endotoxin, trauma, and hemorrhage. I. Certain similarities between the reactions in normal and endotoxin-tolerant rats. J Exp Med 1957; 106: 385-401.
2. Boffa JJ, Arendshorst WJ. Maintenance of renal vascular reactivity contributes to acute renal failure during endotoxemic shock. J Am Soc Nephrol 2005; 16: 117-124.
3. Barrett LK, Orie NN, Taylor V, Stidwill RP, Clapp LH, Singer M. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit Care Med 2007; 35: 2337-2343.
4. Wang F, Gao F, Jing L. Is macrophage migration inhibitory factor (MIF) the "control point" of vascular hyporesponsiveness in septic shock? Med Hypotheses 2005; 65: 1082-1087.
5. Doursout MF, Oguchi T, Fischer UM, Liang Y, Chelly B, Hartley CJ, et al. Distribution of NOS isoforms in a porcine endotoxin shock model. Shock 2008; 29: 692-702.
6. Kozhevnikova LM, Avdonin PP, Sukhanova IF, Avdonin PV. The role of desensitization of glucocorticoid receptors in the development of vascular resistance to endogenous vasoconstrictors in traumatic shock. Vestn Ross Akad Med Nauk 2007: 3-8.
7. Lange M, Morelli A, Ertmer C, Br?king K, Rehberg S, Van Aken H, et al. Role of adenosine triphosphate-sensitive potassium channel inhibition in shock states: physiology and clinical implications. Shock 2007; 28: 394-400.
8. Xu J, Liu L. The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic shock in the rat. Shock 2005; 23: 576-581.
9. Zhao Q, Zhao KS. Inhibition of L-type calcium channels in arteriolar smooth muscle cells is involved in the pathogenesis of vascular hyporeactivity in severe shock. Shock 2007; 28: 717-721.
10. Li T, Liu L, Liu J, Ming J, Xu J, Yang G, et al. Mechanisms of rho kinase regulation of vascular reactivity following hemorrhagic shock in rats. Shock 2008; 29: 65-70.
11. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
12. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 2006; 1: S13-S18.
13. Cainazzo MM, Ferrazza G, Mioni C, Bazzani C, Bertolini A, Guarini S. Cannabinoid CB(1) receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat. Eur J Pharmacol 2002; 441: 91-97.
14. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Wang YW, et al. Role of Ca2+-dependent potassium channel in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. Liver Int 2007; 27: 1045-1055.
15. Fink MP, Homer LD, Fletcher JR. Diminished pressor response to exogenous norepinephrine and angiotensin II in septic, unanesthetized rats: evidence for a prostaglandin-mediated effect. J Surg Res 1985; 38: 335-342.
16. Lange M, Br?king K, Hucklenbruch C, Ertmer C, Van Aken H, Lücke M, et al. Hemodynamic effects of titrated norepinephrine in healthy versus endotoxemic sheep. J Endotoxin Res 2007; 13: 53-57.
17. Bátkai S, Mukhopadhyay P, Harvey-White J, Kechrid R, Pacher P, Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol heart Circ Physiol 2007; 293: H1689-H1695.
18. Gebremedhin D, Lange AR, Campbell WB, Hillard CJ, Harder DR. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am J Physiol 1999; 276: H2085-H2093.
19. O'Sullivan SE, Kendall DA, Randall MD. Further characterization of the time-dependent vascular effects of delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 2006; 317: 428-438.
20. Rajesh M, Mukhopadhyay P, Haskó G, Pacher P. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem Biophys Res Commun 2008; 377: 1248-1252.
21. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 346: 835-840.
22. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997; 100: 1538-1546.
23. Pacher P, Bátkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 2005; 168: 599-625.
24. Kunos G, Pacher P. Cannabinoids cool the intestine. Nature Medicine 2004; 10: 678-679.
25. Su JY, Vo AC. 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur J Pharmacol 2007; 559: 189-195.
26. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 2008; 108: 308-319.
27. Kurz CM, Gottschalk C, Schlicker E, Kathmann M. Identification of a presynaptic cannabinoid CB1 receptor in the guinea-pig atrium and sequencing of the guinea-pig CB1 receptor. J Physiol Pharmacol 2008; 59: 3-15.
28. Oropeza VC, Mackie K, Van Bockstaele EJ. Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex. Brain Res 2007; 1127: 36-44.